Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles

Trial Profile

Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Isavuconazonium (Primary) ; Isavuconazonium (Primary) ; Posaconazole (Primary) ; Posaconazole (Primary) ; Voriconazole (Primary) ; Voriconazole (Primary)
  • Indications Mycoses
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 01 May 2017 Planned End Date changed from 1 Jan 2022 to 31 Dec 2021.
    • 01 May 2017 Planned primary completion date changed from 1 Jan 2022 to 31 Dec 2021.
    • 02 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top